Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
June 30th, 2021
Here we provide a detailed procedure for large-scale production of research-grade AAV vectors using adherent HEK 293 cells grown in cell stacks and affinity chromatography purification. This protocol consistently yields >1 x 1013 vector genomes/mL, providing vector quantities appropriate for large animal studies.
Overview
This protocol outlines a cost-effective method for producing high-titer, research-grade AAV viral vectors using adherent HEK293 cells. The approach is designed for efficiency and high purity, making it suitable for preclinical studies in large animal models.
Key Study Components
Area of Science
- Gene therapy
- Viral vector production
- Cell culture techniques
Background
- AAV vectors are crucial for gene therapy applications.
- HEK293 cells are commonly used for AAV production.
- High titer and purity are essential for effective research outcomes.
- This method minimizes handling disruptions to cells.
Purpose of Study
- To provide a reliable protocol for AAV vector production.
- To enhance the efficiency of viral vector generation.
- To support research in gene therapy and related fields.
Methods Used
- Utilization of adherent HEK293 cells in cell culture chambers.
- Affinity chromatography for purification of AAV vectors.
- Collection of cells at 80% confluency for optimal yield.
- Time-efficient procedures to reduce cell handling.
Main Results
- Consistent yield of >1 x 1013 vector genomes/mL.
- High purity of produced AAV vectors.
- Protocol suitable for large animal studies.
- Adaptable for various AAV serotypes.
Conclusions
- This protocol significantly aids in the production of AAV vectors.
- It is a valuable tool for advancing gene therapy research.
- Potential for broader applications in viral vector production.
Frequently Asked Questions
Executive Industry Relevance
Transitioning AAV gene therapy candidates from rodent to large animal models requires scalable, high-titer vector production that maintains purity and functional integrity. This protocol enables research teams to generate research-grade AAV at quantities suitable for preclinical studies in large animals, addressing a critical bottleneck in translational gene therapy pipelines. By leveraging adherent HEK293 cell stacks, the method supports robust vector supply for target validation and dose-ranging studies in disease-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables production of high-titer AAV for in vivo target validation in large animal models.
- Supports mechanistic de-risking by facilitating transgene expression studies across species.
- Provides a scalable platform for functional assessment of novel gene therapy constructs.
Screening & Assay Development
- Delivers reproducible, high-purity AAV preparations for downstream assay development.
- Facilitates standardization of vector input for quantitative transduction efficiency studies.
- Enables reliable comparison of AAV serotype performance in preclinical settings.
Translational & Preclinical Research
- Aligns vector production scale with requirements for large animal dosing and biomarker analysis.
- Supports continuity from rodent proof-of-concept to translational efficacy studies.
- Reduces risk of supply-related delays in preclinical advancement decisions.
Pipeline & Workflow Integration
This method bridges the gap between early discovery and preclinical validation by enabling scalable AAV production for large animal studies, a key inflection point in gene therapy development.
- Discovery Biology: Provides sufficient vector for robust hypothesis testing and pathway interrogation in vivo.
- Screening: Ensures assay readiness and reproducibility through standardized, high-titer vector supply.
- Analytics: Supports quantitative measurement of transgene expression and vector purity for cross-study comparison.
- Translational Research: Facilitates dose-ranging and biomarker alignment in disease-relevant large animal models.
- Enterprise Reuse: Offers a reusable, adaptable production workflow for multiple AAV serotypes and constructs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in translational models and reduces mechanistic ambiguity.
- Operational Value: Standardizes vector production, improving reproducibility and scalability across studies.
- Strategic Value: Accelerates go/no-go decisions and optimizes resource allocation in gene therapy portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on robust preclinical data.
Implementation Considerations
- Requires expertise in adherent cell culture and viral vector purification.
- Needs access to cell stack chambers, centrifugation, and chromatography infrastructure.
- Demands cross-team standardization of titering and purity validation protocols.
- Adaptable to various AAV serotypes that bind heparan sulfate, with protocol modifications as needed.
- Production scale may be limited by available cell culture and purification capacity.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:46
Double Plasmid Transfection of HEK293 Cells in Cell Stacks
2:30
Harvesting Adeno-Associated Virus AAV and Chemical Lysis of The Transfected HEK293 Cells
3:23
AAV Vector Purification Using Heparin Affinity Chromatography
5:45
Results: Serum Human Monoclonal Antibody (hIgG) Expression in Animals Upon Administration of AAV6.2FF-hIgG
6:41
Conclusion
